ArticleCancer research2010
High-throughput screening for salmonella avirulent mutants that retain targeting of solid tumors.
Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 48 citations in OpenAlex.
- Bacterial engineering for cancer therapy.Nature cancer · 2026Review
- Intracellular delivery of oncolytic viruses with engineered Salmonella causes viral replication and cell death.iScience · 2024Article
- Attenuated mutants ofExperimental biology and medicine (Maywood, N.J.) · 2024Article
- Engineer a double team of short-lived and glucose-sensing bacteria for cancer eradication.Cell reports. Medicine · 2023Article
- Targeting primary and metastatic tumor growth in an aggressive breast cancer by engineered tryptophan auxotrophicMolecular therapy oncolytics · 2022Article
- Phenotypic characterization of auxotrophic mutant of nontyphoidal Salmonella and determination of its cytotoxicity, tumor inhibiting cytokine gene expression in cell line models.Archives of microbiology · 2021Article
- Optimized AttenuatedFrontiers in microbiology · 2021Article
- AttenuatedVaccines · 2020Article
- Bacterial delivery of the anti-tumor azurin-like protein Laz to glioblastoma cells.AMB Express · 2020Article
- Amino Acid Biosynthetic Pathways Are Required forAntimicrobial agents and chemotherapy · 2019Article
- Review
- The motility regulator flhDC drives intracellular accumulation and tumor colonization of Salmonella.Journal for immunotherapy of cancer · 2019Article
- Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models.Cancer gene therapy · 2018Article
- Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions.Frontiers in microbiology · 2018Article
- The inhibition of indoleamine 2, 3-dioxygenase 1 by connexin 43.International journal of medical sciences · 2017Article
- Treatment of Neuroblastoma with an Engineered "Obligate" AnaerobicJournal of Cancer · 2017Article
- The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009.Oncotarget · 2016Article
- Article
- Solid tumors provide niche-specific conditions that lead to preferential growth of Salmonella.Oncotarget · 2016Article
- Salmonella Bacterial Monotherapy Reduces Autochthonous Prostate Tumor Burden in the TRAMP Mouse Model.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
Abstract
Salmonella has a natural ability to target a wide range of tumors in animal models. However, strains used for cancer therapy have generally been selected only for their avirulence rather than their tumor-targeting ability. To select Salmonella strains that are avirulent and yet efficient in tumor targeting, a necessary criterion for clinical applications, we measured the relative fitness of 41,000 Salmonella transposon insertion mutants growing in mouse models of human prostate and breast cancer. Two classes of potentially safe mutants were identified. Class 1 mutants showed reduced fitness in normal tissues and unchanged fitness in tumors (e.g., mutants in htrA, SPI-2, and STM3120). Class 2 mutants showed reduced fitness in tumors and normal tissues (e.g., mutants in aroA and aroD). In a competitive fitness assay in human PC-3 tumors growing in mice, class 1 mutant STM3120 had a fitness advantage over class 2 mutants aroA and aroD, validating the findings of the initial screening of a large pool of transposon mutants and indicating a potential advantage of class 1 mutants for delivery of cancer therapeutics. In addition, an STM3120 mutant successfully targeted tumors after intragastric delivery, opening up the oral route as an option for therapy administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.